Peptide synthesis is the method of creating peptide bonds, which are made up of numerous amino acids linked by amide bonds. Peptides are pharmaceutical molecules with great activity and selectivity. Because of the diversity of their biological effects, they are used in a wide range of therapeutic fields. Peptides are increasingly being regarded as potential active pharmacological components in drug development due to their large chemical space, relative simplicity of synthesis, low toxicity, high biological activity, accessible availability, and high specificity. Peptides produce billions of dollars in income in three key therapeutic areas: cancer, diabetes, and obesity. Peptides are increasingly being employed to treat neurological and cardiovascular illnesses, as well as kidney failure and uncommon diseases. With around 700 peptide medicines and therapeutic peptides, this number is anticipated to skyrocket
It’s being expected that by 2030, the Peptide Synthesis market cap will hit USD 68.7 billion at a CAGR growth of about 6.4%.
Covid-19 Impact & Market Status:
The pandemic of COVID-19 has prompted large biotechnology and pharmaceutical companies, as well as peptide synthesis companies, to invest in peptide-based vaccine development and therapeutic. Due to rising demand for vaccinations and peptide-based treatments, peptide synthesis has pushed to the forefront. The peptide-based method represents a turning point since peptides have demonstrated unique qualities of selectivity towards certain targets. SARS-CoV-2 T-cell epitopes generated from multiple viral proteins are combined with the Toll-like receptor 1/2 agonist XS15 emulsified in Montanide ISA51 VG to induce significant SARS-CoV-2 T-cell immunity against COVID-19 in CoVac-1, a peptide-based vaccination candidate.
North America held the highest share in the Market
North America held the highest share of the peptide synthesis market, with 37.6 percent, followed by Europe and Asia Pacific, with 29.8 percent and 26 percent, respectively. The high incidence of chronic illnesses, expanding investments in the creation of structure-based drug designs, growing genomes and proteomics research, and a growing focus on generating personalised therapies are all contributing reasons to North America's big proportion of the worldwide market. In 2021, the United States ruled the North American market. The considerable contribution of the United States can be linked to the country's burgeoning life science research activities and the rising prevalence of chronic disorders and cancer.
The notion of customized therapy with the best response and broadest safety margin to enable better patient care has sparked interest in personalized treatment. Proteomic analysis is an effective and appealing tool for assessing the molecular profiles of different tissues, whether healthy or diseased.
From USD 515 million in 2022 to USD 899 million in 2029, the worldwide peptide synthesis market is predicted to increase at a CAGR of 7.2 percent.
The occurrence of a robust therapeutic pipeline is projected to promote the growth of the peptide synthesis market in the foreseeable years. Furthermore, the focus of numerous authorities on the advancement of advanced degrees of peptide synthesizers is expected to drive the peptide synthesis market forward. The lack of streamlined rules for the advancement of medicinal peptides, on the other hand, is expected to stymie the peptide synthesis market's growth throughout the forecast period.
Furthermore, the increase in research expenses would create further chances for the peptide synthesis market to grow in the next years. On the other hand, difficulties in improving peptide synthesis may provide a further impediment to the peptide synthesis market's expansion in the near future.
The major market players of Peptide Synthesis Market are Kaneka Corporation (Japan), Merck KGaA (Germany), Bachem, GenScript Biotech Corporation (China), and Thermo Fisher Scientific Inc. (US).
Major Developments in Peptide Synthesis Market:
- CEM Corporation launched Liberty PRO, the world's first large-scale automated microwave peptide synthesis, in May 2019. The system can produce 1 kilogramme of crude peptide every batch in reaction vessels up to 15 litres, with unrivalled purity, waste reduction, and speed, fueling market revenue share.
- Due to the USFDA's rapid drug approval programme, favourable earlier approval of peptide pharmaceuticals is expected to fuel market expansion in this region over the projected period, leading to its outstanding market dominance in the global peptide synthesis market.
- Neoantigen Specific Peptide Synthesis Service was launched by GenScript in April 2020 for precision immuno-oncology therapy development.
- JPT Peptide Technologies released ready-to-use peptide tools in April 2020 to research and profile the immune response to SARS-CoV-2 infection.
Peptide Synthesis Market Scope
|Forecast Unit||Value (USD)|
|Revenue forecast in 2028||USD 899 million.|
|Growth Rate||CAGR of 7.2% during 2021-2028|
|Segment Covered||Reagent, Application, Regions|
|Regions Covered||North America, Europe, Asia Pacific, South America, Middle East & Africa|
|Key Players Profiled||Kaneka Corporation (Japan), Merck KGaA (Germany), Bachem, GenScript Biotech Corporation (China), and Thermo Fisher Scientific Inc. (US). & among others.|
Key Segments of Peptide Synthesis Market
Reagent Overview, 2022-2029 (USD Million)
- Amino Acid
Application Overview, 2022-2029 (USD Million)
Regional Overview, 2022-2029 (USD Million)
- North America
- Rest of Europe
- Asia Pacific
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa